Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5‐year follow‐up results from the STAMPEDE randomised trial (NCT00268476)
Nicholas D. James(Royal Marsden NHS Foundation Trust), Jacob Tanguay(Velindre Cancer Centre), Neil McPhail(Cancer Research UK), Emma Gray(Wellcome Sanger Institute), John M. Russell, Silke Gillessen(Institute of Oncology Research), Ruth E. Langley(MRC Clinical Trials Unit at UCL), Adrian Cook(University College London), Angus Robinson(Royal Sussex County Hospital), Peter Hoskin(University of Manchester), Narayanan Srihari(Shrewsbury and Telford Hospital NHS Trust), Dan Ford(Queen Elizabeth Hospital Birmingham), Warren Grant(Cheltenham General Hospital), David P. Dearnaley(Royal Marsden NHS Foundation Trust), Malcolm D. Mason(Royal Marsden Hospital), William Cross(Leeds Teaching Hospitals NHS Trust), Clare Gilson(Cancer Research UK), Caroline Manetta(University Hospitals Sussex NHS Foundation Trust), Robert J. Jones(Beatson West of Scotland Cancer Centre), Joe M. O’Sullivan(San Antonio College), Joanna Gale(Queen Alexandra Hospital), Andrew Protheroe(University of Oxford), Omi Parikh(Royal Blackburn Teaching Hospital), Noel W. Clarke(The Christie NHS Foundation Trust), David Matheson(MRC Clinical Trials Unit at UCL), Johann S. de Bono(Royal Marsden NHS Foundation Trust), Duncan C. Gilbert(Royal Sussex County Hospital), Carla Perna(Royal Surrey NHS Foundation Trust), Mohammad Muneeb Khan(Scarborough General Hospital), Cheryl Pugh(MRC Clinical Trials Unit at UCL), Alison Birtle(University of Lancashire), Hannah Rush(University College London), Dominik Berthold(University Hospital of Lausanne), Susannah Brock, Carmel Pezaro(Royal Marsden NHS Foundation Trust), Isabel Syndikus(San Antonio College), Alex Hoyle(The Christie NHS Foundation Trust), Chris Brawley(Cancer Research UK), Carlos Díaz-Montaña(University College London), Chris Parker(Royal Marsden NHS Foundation Trust), Sarah Maria Rudman(Guy's and St Thomas' NHS Foundation Trust), Zafar Malik(Cancer Research UK), D.J. Sheehan(Royal Devon & Exeter NHS Foundation Trust), Michelle Buckner(MRC Clinical Trials Unit at UCL), Simon Chowdhury(Sarah Cannon Research Institute), A.W.S. Ritchie(MRC Clinical Trials Unit at UCL), Gerhardt Attard(London Cancer), Robin Millman(MRC Clinical Trials Unit at UCL), Prantik Das(Royal Derby Hospital)
Cited by 79
Related Papers
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
|New England Journal of Medicine|2013|3.3k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k